跳至主要内容
临床试验/NCT05945394
NCT05945394招募中不适用

The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2023年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
800
试验地点
1
主要终点
stenosis of coronary artery

研究概览

简要总结

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

详细描述

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with suspected coronary heart disease
  • patients received coronary angiography

排除标准

  • NYHA III-IV
  • malignant tumor
  • acute infection
  • thyroid dysfunction

结局指标

主要结局

stenosis of coronary artery

时间窗: 1 week

The stenosis of coronary artery based on the results of coronary angiography

次要结局

  • coronary artery calcium(1 week)

研究者

发起方
Nanjing Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jin Geng

associate doctor

Nanjing Medical University

研究点 (1)

Loading locations...

相似试验